» Articles » PMID: 30784674

Is Sacubitril/Valsartan Antifibrotic?

Overview
Date 2019 Feb 21
PMID 30784674
Citations 5
Authors
Affiliations
Soon will be listed here.
Citing Articles

Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction.

Bolla G, Fedele A, Faggiano A, Sala C, Santangelo G, Carugo S BMC Cardiovasc Disord. 2022; 22(1):217.

PMID: 35562650 PMC: 9101988. DOI: 10.1186/s12872-022-02647-0.


Cardiac Fibrosis and Fibroblasts.

Kurose H Cells. 2021; 10(7).

PMID: 34359886 PMC: 8306806. DOI: 10.3390/cells10071716.


Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension.

Kia D, Benza E, Bachman T, Tushak C, Kim K, Simon M J Am Heart Assoc. 2020; 9(13):e015708.

PMID: 32552157 PMC: 7670537. DOI: 10.1161/JAHA.119.015708.


Differential effects of low-dose sacubitril and/or valsartan on renal disease in salt-sensitive hypertension.

Polina I, Domondon M, Fox R, Sudarikova A, Troncoso M, Vasileva V Am J Physiol Renal Physiol. 2020; 319(1):F63-F75.

PMID: 32463726 PMC: 7468826. DOI: 10.1152/ajprenal.00125.2020.


Silibinin Augments the Antifibrotic Effect of Valsartan Through Inactivation of TGF-β1 Signaling in Kidney.

Liu R, Wang Q, Ding Z, Zhang X, Li Y, Zang Y Drug Des Devel Ther. 2020; 14:603-611.

PMID: 32103902 PMC: 7026148. DOI: 10.2147/DDDT.S224308.